Loading
A phase 1/2 trial in triple-negative breast cancer, run by Mainline Biosciences (Shanghai) Co., Ltd, now recruiting.
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors is a phase 1/2, interventional study registered as NCT06840821 by Mainline Biosciences (Shanghai) Co., Ltd, with a registry enrolment figure of 156 participants, started 2025-05-08 and due to reach its primary completion in 2028-07-04. Interventions recorded: MB0151 for injection. Conditions listed: Advanced Solid Tumors. Triple-negative eligibility wording from the registry: "The subject must have a solid tumor confirmed by histology or cytology, and belong to one of the following categories: 1) locally advanced or metastatic SCLC, which has received standard treatment in the past and developed progress or intolerance; 2) Low-grade, medium-grade or high-grade locally adv". Sites: China. No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.